EcoDrugPlus

Integrin Beta 3a

Ensembl ID : ENSDLAG00005020604
Gene Symbol: ITGB3A
1 Cross references
204 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSDLAG00005010523
Gene Symbol: ITGA4
1 Cross references
226 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSDLAG00005015910
Gene Symbol: ITGB6
1 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSDLAG00005019323
Gene Symbol: ITGB8
1 Cross references
207 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSDLAG00005012699
Gene Symbol: ITGA5
1 Cross references
206 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSDLAG00005000845
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSDLAG00005001217
Gene Symbol: ITGB5
1 Cross references
211 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSDLAG00005014882
Gene Symbol: IRAK4
1 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSDLAG00005026063
Gene Symbol: IDH1
1 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSDLAG00005010584
Gene Symbol: IDH2
1 Cross references
196 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1b

Ensembl ID : ENSDLAG00005008271
Gene Symbol: KEAP1B
1 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSDLAG00005012762
Gene Symbol: KDR
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).